Applies to Employer plans.
Depends on your plan's benefitWeight loss must NOT be excluded from coverage under the patient's pharmacy benefit. Applies to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open for weight loss agents on coverage delay.
Qualification pathways
You can qualify through any one of these.
Adult Weight Management
All of:
- Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
- Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
- Patient is an adult (18 years of age or over)
- Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
- Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
- Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
- Patient is currently on and will continue weight management regimen
- Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
- Patient does NOT have any FDA labeled contraindications
- Patient's age is within FDA labeling OR there is support for use at patient's age
- Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction
Plus any one of:
- BMI ≥ 30 kg/m2
- BMI ≥ 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
- BMI ≥ 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)
Pediatric Weight Management (12-17 years)
All of:
- Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
- Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
- Patient is pediatric (12 to 17 years of age)
- Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
- Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
- Patient will NOT use the requested agent in combination with another weight loss agent
- Patient is currently on and will continue weight management regimen
- Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
- Patient does NOT have any FDA labeled contraindications
- Patient's age is within FDA labeling OR there is support for use at patient's age
- Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction
Plus any one of:
- BMI ≥ 95th percentile for age and sex
- BMI ≥ 30 kg/m2
- BMI ≥ 85th percentile for age and sex AND at least one severe weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)
Repeat Course of Therapy (prior weight loss agent in past 12 months)
All of:
- Patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months
- Prescriber anticipates success with repeating therapy with any targeted weight loss agent
- All other standard weight management criteria met
Documentation to bring
- Documentation of BMI (≥ 30 kg/m2, or ≥ 27 kg/m2 with comorbidity, or ≥ 25 kg/m2 if South/Southeast/East Asian)
- Documentation of 6-month weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
- Documentation of weight loss less than 1 pound per week on weight management regimen prior to pharmacotherapy
- Documentation that weight loss is not excluded from coverage under the patient's pharmacy benefit
- Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful
- For pediatric patients: documentation of age (12-17), BMI percentile for age and sex, and qualifying comorbidities if applicable
- For repeat course: documentation of prior targeted weight loss agent use and prescriber attestation of anticipated success
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- Renewal: For renewal: patient has achieved and maintained ≥ 5% weight loss from baseline (prior to initiation of the requested agent), OR patient has received less than 52 weeks of therapy on the maximum-tolerated dose. Pediatric renewal also requires current BMI ≥ 85th percentile for age and sex. Patient must continue weight management regimen and not combine with another weight loss agent or GLP-1.
Not covered when
- Co-administration with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
- Co-administration with another GLP-1 receptor agonist
- Any FDA labeled contraindications
- Weight loss coverage excluded from pharmacy benefit
Policy note: Policy applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies. Weight loss agents on coverage delay apply to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open. For the 6-month lifestyle program, the patient must not have lost ≥ 1 lb/week (i.e., inadequate response to lifestyle). For renewal: Zepbound weight loss renewal requires either < 52 weeks of therapy on maximum-tolerated dose OR ≥ 5% weight loss from baseline. Pediatric renewal additionally requires current BMI ≥ 85th percentile. Managed by Prime Therapeutics.
Policy effective April 1, 2026 · verified June 5, 2026 · source: BCBS Minnesota Employer / Commercial Insurance prior authorization policy · View policy document (PDF)